Literature DB >> 24976364

Eicosapentaenoic acid/arachidonic acid ratio as a possible link between non-alcoholic fatty liver disease and cardiovascular disease.

Tomokazu Ishitobi1, Hideyuki Hyogo, Hiromi Kan, Akira Hiramatsu, Koji Arihiro, Hiroshi Aikata, Kazuaki Chayama.   

Abstract

AIM: The main causes of mortality from non-alcoholic fatty liver disease (NAFLD) are cardiovascular disease (CVD) and malignancy. Eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio is known to be associated with CVD. However, a possible link between EPA/AA ratio and NAFLD is not well known. In this study, we investigated EPA/AA ratio in Japanese patients with NAFLD.
METHODS: Two hundred and fifty-four patients with biopsy-proven NAFLD were retrospectively enrolled. Serum EPA/AA ratios were examined for each generation (<35, 35-44, 45-54, 55-64, ≥65 years), and the differences of EPA/AA ratios were evaluated based on steatotic grades and fibrotic stages.
RESULTS: EPA/AA ratio in NAFLD patients was decreased compared to that reported in age-matched healthy controls. EPA/AA ratio, body mass index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and steatotic grades in younger NAFLD patients were significantly worse than those in older NAFLD patients. Fasting glucose, hemoglobin A1c and fibrotic stages in older NAFLD patients were significantly higher than those in younger NAFLD patients. No relation was found between EPA/AA ratio and histological findings.
CONCLUSION: EPA/AA ratio was lower in NAFLD, especially in younger NAFLD patients. Considering the high mortality from CVD in NAFLD patients, low EPA/AA ratio in young age may influence the increased prevalence of CVD in their older age. EPA/AA ratio is suggested to be a possible link between NAFLD and CVD, and would become a useful marker for CVD in NAFLD.
© 2014 The Japan Society of Hepatology.

Entities:  

Keywords:  cardiovascular disease; eicosapentaenoic acid/arachidonic acid; non-alcoholic fatty liver disease

Year:  2014        PMID: 24976364     DOI: 10.1111/hepr.12382

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  3 in total

1.  Intestinal Failure-Associated Liver Disease and Eicosapentaenoic Acid/Arachidonic Acid Ratio.

Authors:  Wataru Miura; Nobuhiko Nagano; Ryota Kato; Aya Okahashi; Kayo Yoshikawa; Kensuke Ohashi; Tsugumichi Koshinaga; Ichiro Morioka
Journal:  Indian J Pediatr       Date:  2019-02-13       Impact factor: 1.967

2.  Fads3 modulates docosahexaenoic acid in liver and brain.

Authors:  Ji Yao Zhang; Xia Qin; Allison Liang; Ellen Kim; Peter Lawrence; Woo Jung Park; Kumar S D Kothapalli; J Thomas Brenna
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2017-07-08       Impact factor: 4.006

3.  PNPLA3 Genotype, Arachidonic Acid Intake, and Unsaturated Fat Intake Influences Liver Fibrosis in Hispanic Youth with Obesity.

Authors:  Roshonda B Jones; Lide Arenaza; Claudia Rios; Jasmine F Plows; Paige K Berger; Tanya L Alderete; Jennifer L Fogel; Krishna Nayak; Passant Mohamed; Darryl Hwang; Suzanne Palmer; Frank Sinatra; Hooman Allayee; Rohit Kohli; Michael I Goran
Journal:  Nutrients       Date:  2021-05-12       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.